Clinical Trial Results:
Phase III Trials Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx®, Doxil®) for Women (age 66 years or older) with Endocrine Nonresponsive Breast Cancer Who Are NOT Suitable for Being Offered a “Standard Chemotherapy Regimen”
Summary
|
|
EudraCT number |
2005-003434-18 |
Trial protocol |
SE HU SI IT BE FR |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
17 Mar 2021
|
First version publication date |
17 Mar 2021
|
Other versions |
|
Summary report(s) |
IBCSG 32-05/ CASA Publication |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.